Two Words to
Rewrite the Story of Fatty Liver Disease: CLINICAL RESEARCH

If you’re managing type 2 diabetes, high blood pressure, or obesity, you might be at higher risk for fatty liver disease non-alcoholic fatty liver disease metabolic dysfunction-associated steatotic liver disease (MASLD).

While its name has evolved, our mission remains clear: understanding this condition better. You can join researchers in the SYNERGY-Outcomes Study to explore a potential treatment option and write the next chapter in liver health.
See If You May Qualify

If you’re managing type 2 diabetes, high blood pressure, or obesity, you might be at higher risk for fatty liver disease non-alcoholic fatty liver disease metabolic dysfunction-associated steatotic liver disease (MASLD).

While its name has evolved, our mission remains clear: understanding this condition better. You can join researchers in the SYNERGY-Outcomes Study to explore a potential treatment option and write the next chapter in liver health.
See If You May Qualify

What is the
 SYNERGY-Outcomes Study

SYNERGY-Outcomes is a phase 3 clinical research study evaluating several different investigational medicines in adults who have, or are at elevated risk for, metabolic dysfunction‑associated steatotic liver disease (MASLD), also known as fatty liver disease.

The goal is to stop MASLD from progressing to serious liver complications.
No Liver Biopsy Required for Enrollment: Unlike many fatty liver studies that rely on invasive liver biopsies, this study uses only noninvasive diagnostic procedures to measure liver fat during screening. Throughout the course of the study, a liver biopsy may be needed to check if your liver disease has progressed.

You may be able to participate in the
SYNERGY-Outcomes Study if you:

Are at least 18 years old
Have or are at risk for MASLD
Have a BMI of ≥ 25 kg/m2
No Liver Biopsy Required for Enrollment: Unlike many fatty liver studies that rely on invasive liver biopsies, this study uses only noninvasive diagnostic procedures to measure liver fat during screening. Throughout the course of the study, a liver biopsy may be needed to check if your liver disease has progressed.

If you are interested in participating, the study doctor or staff will review study criteria with you.

If you are interested in participating, the study doctor or staff will review additional study criteria with you.

Qualified participants may receive all study-related medicines and study-related care at no cost. Participants may be reimbursed for travel and expenses.
See If You May Qualify

Facts About MASLD

MASLD vs. MASH: What’s the difference?

  • MASLD (metabolic dysfunction–associated steatotic liver disease) is a liver condition where fat accumulates in the liver (hepatic steatosis) in individuals with metabolic risk factors such as type 2 diabetes or obesity. MASLD can be diagnosed through noninvasive tests or a liver biopsy.
  • MASH (metabolic dysfunction–associated steatohepatitis) is diagnosed when a person with MASLD also shows evidence of liver inflammation and possibly liver scarring (fibrosis). These features can only be seen on a liver biopsy.

What is high-risk MASLD?

Patients with high-risk MASLD face a significantly increased chance of developing major liver problems, such as tissue scarring (cirrhosis) and liver failure. This “high-risk” status can be identified in 2 ways:
  • Through a liver biopsy showing advanced fibrosis, or
  • Using noninvasive tests that can predict major liver problems, such as:
  • An imaging technique that measures liver stiffness (e.g., FibroScan)
  • A blood test that provides an Enhanced Liver Fibrosis (ELF) score
Importantly, high-risk MASLD patients who are identified by noninvasive tests face similar risks to those with moderate liver scarring as seen on a liver biopsy. Thanks to noninvasive tests, clinicians can tell a patient’s risk for developing major liver problems without the need for invasive biopsies.

Why was the name changed from NAFLD to MASLD?

  • Previously known as non-alcoholic fatty liver disease (NAFLD), this condition has been renamed to MASLD to reduce stigma and better reflect its connection to metabolic health (how your body processes food, manages blood sugar, and maintains healthy cholesterol levels).1, 2

How does MASLD affect the liver?

  • MASLD is the most common cause of chronic liver disease, affecting approximately 1 in 4 people in the United States.1, 2, 3
  • MASLD can cause liver damage that can lead to inflammation, cirrhosis, and possible need for a liver transplant.3
  • It is normal for the liver to contain some fat. However, if more than 5–10% of the liver’s weight is fat, then it is called a fatty liver, or steatosis.3

What are the symptoms and risk factors for MASLD?

  • MASLD is a silent disease, meaning most people won’t experience symptoms until the disease progresses. However, some people may experience fatigue or discomfort or pain in the abdomen.1, 3
  • Risk factors for MASLD include obesity, high blood pressure, and type 2 diabetes.2, 3
  • Many people think that liver disease occurs because of alcohol use, but MASLD can develop in people who drink little or no alcohol.3

Where can I learn more?

To learn more, talk to your doctor or visit:
American Liver Foundation

  1. https://pmc.ncbi.nlm.nih.gov/articles/PMC10583766/

  2. https://pubmed.ncbi.nlm.nih.gov/38228377/

  3. https://liverfoundation.org/liver-diseases/fatty-liver-disease/nonalcoholic-fatty-liver-disease-nafld/

Interested in the
 SYNERGY-Outcomes Study?

See If You May Qualify
Created by CTM
Privacy Policy Legal Notice Consumer Health Privacy Notice Cookie Notice
Your Privacy Choice
© 2025 Clinical Trial Media. All Rights Reserved. The images depicted contain models and are being used for illustrative purposes only.
Created by CTM
© 2025 Clinical Trial Media. All Rights Reserved. The images depicted contain models and are being used for illustrative purposes only.
Privacy Policy Legal Notice Consumer Health Privacy Notice Cookie Notice
Your Privacy Choice